Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Metrics to compare | HYPE3 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHYPE3PeersSector | |
|---|---|---|---|---|
P/E Ratio | 11.7x | 11.8x | −0.4x | |
PEG Ratio | −1.09 | −0.06 | 0.00 | |
Price/Book | 1.1x | 1.6x | 2.6x | |
Price / LTM Sales | 1.8x | 2.2x | 3.1x | |
Upside (Analyst Target) | 36.0% | 35.1% | 58.8% | |
Fair Value Upside | Unlock | 13.9% | 9.2% | Unlock |